This vascular running phenomenon represents a unique therapeutic approach
Even so, doctors expect peptide use to spike, despite lack of evidence that all of these substances work or are safe
Consultation is Key Before diving into sclerotherapy, schedule a comprehensive consultation with a qualified vascular specialist
The reasons cited by the FDA included concerns about immunogenicity, peptide impurity characterization challenges, and the lack of adequate safety data from human clinical trials
Then, 1000 mcg weekly for a month, and 1000 mcg monthly after that
(All committee members underwent the same ethics review and vetting process required of all FDA advisory committee members, Emily Hilliard, a spokesperson for the Department of Health and Human Services, told me in an email.) The decision is only a recommendation, and the FDA would still need to sign off on an actual rule change